KR20240136972A - 1,3,4,7-테트라하이드로-2H-피롤로[3',2':5,6]피리도[2,3-b][1,4]옥사제핀Bcl-2 억제제 - Google Patents

1,3,4,7-테트라하이드로-2H-피롤로[3',2':5,6]피리도[2,3-b][1,4]옥사제핀Bcl-2 억제제 Download PDF

Info

Publication number
KR20240136972A
KR20240136972A KR1020247023725A KR20247023725A KR20240136972A KR 20240136972 A KR20240136972 A KR 20240136972A KR 1020247023725 A KR1020247023725 A KR 1020247023725A KR 20247023725 A KR20247023725 A KR 20247023725A KR 20240136972 A KR20240136972 A KR 20240136972A
Authority
KR
South Korea
Prior art keywords
dimethyl
pyrrolo
pyrido
dihydro
pyrazino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023725A
Other languages
English (en)
Korean (ko)
Inventor
조지 에이 도허티
비크람 바트
패트릭 브래디
위자 다이
졘춘 궁
?컬? 궁
앤드류 에스 주드
앤드류 제이 수어스
이윈 위
Original Assignee
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애브비 인코포레이티드 filed Critical 애브비 인코포레이티드
Publication of KR20240136972A publication Critical patent/KR20240136972A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020247023725A 2022-01-21 2023-01-20 1,3,4,7-테트라하이드로-2H-피롤로[3',2':5,6]피리도[2,3-b][1,4]옥사제핀Bcl-2 억제제 Pending KR20240136972A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267018P 2022-01-21 2022-01-21
US63/267,018 2022-01-21
PCT/US2023/060944 WO2023141536A1 (en) 2022-01-21 2023-01-20 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors

Publications (1)

Publication Number Publication Date
KR20240136972A true KR20240136972A (ko) 2024-09-19

Family

ID=85382827

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023725A Pending KR20240136972A (ko) 2022-01-21 2023-01-20 1,3,4,7-테트라하이드로-2H-피롤로[3',2':5,6]피리도[2,3-b][1,4]옥사제핀Bcl-2 억제제

Country Status (13)

Country Link
US (3) US11964990B2 (https=)
EP (1) EP4466273A1 (https=)
JP (2) JP7714811B2 (https=)
KR (1) KR20240136972A (https=)
CN (1) CN119053610A (https=)
AR (1) AR128310A1 (https=)
AU (1) AU2023210279A1 (https=)
CA (1) CA3242074A1 (https=)
CO (1) CO2024009334A2 (https=)
IL (1) IL312709A (https=)
MX (1) MX2024008840A (https=)
TW (1) TW202340210A (https=)
WO (1) WO2023141536A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964990B2 (en) * 2022-01-21 2024-04-23 Abbvie Inc. 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
CN117820134A (zh) * 2024-01-10 2024-04-05 山东盛安贝新材料有限公司南京分公司 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018322059C1 (en) 2017-08-23 2024-09-12 Guangzhou Lupeng Pharmaceutical Company Ltd. BCL-2 inhibitors
US12220419B2 (en) 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
KR20220158725A (ko) 2020-02-24 2022-12-01 광조우 루펭 파마슈티칼 컴퍼니 엘티디. Bcl2 억제제를 함유하는 핫 멜트 압출 고체 분산체
US11964990B2 (en) * 2022-01-21 2024-04-23 Abbvie Inc. 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors

Also Published As

Publication number Publication date
WO2023141536A1 (en) 2023-07-27
US11964990B2 (en) 2024-04-23
JP7714811B2 (ja) 2025-07-29
IL312709A (en) 2024-07-01
CN119053610A (zh) 2024-11-29
CO2024009334A2 (es) 2024-07-18
JP2025160251A (ja) 2025-10-22
AR128310A1 (es) 2024-04-17
AU2023210279A1 (en) 2024-05-23
US20250066388A1 (en) 2025-02-27
US20260028356A1 (en) 2026-01-29
EP4466273A1 (en) 2024-11-27
JP2025504382A (ja) 2025-02-12
MX2024008840A (es) 2024-07-25
TW202340210A (zh) 2023-10-16
US20230234971A1 (en) 2023-07-27
CA3242074A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
JP7279073B2 (ja) Ｏ－置換セリン誘導体の製造方法
JP2025160251A (ja) １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤
CA2909620C (en) Staple and suture polypeptides and their uses
EP2651964B1 (en) Cross-linked peptides and proteins, methods of making same, and uses thereof
JP2017039701A (ja) 安定化させたｐ５３ペプチドおよびその使用法
TW201920194A (zh) 大環ｍｃｌ-１抑制劑及使用方法
JP5951006B2 (ja) 大環状デプシペプチド類の製造方法および新規中間体
CA3046171A1 (en) Multicyclic peptides and methods for their preparation
EP3907234A1 (en) Preparation method for and intermediate of drug-linker for antibody drug conjugate mc-mmaf
ES2634693T3 (es) Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil¿oxazol como agonistas del receptor de ALX
CN105585583B (zh) 一种非肽类凋亡抑制蛋白拮抗剂及其合成方法与应用
Chen et al. Total synthesis and a systematic structure-activity relationship study of WAP-8294A2
WO2022049005A1 (en) High affinity macrocyclic fkb51-inhibitors for treatment of psychiatric disorders
Zhang et al. Design, Synthesis, and Structure–Activity Relationship Study of Epoxysuccinyl–Peptide Derivatives as Cathepsin B Inhibitors
Stasevych et al. The New 1, 2, 3-Triazolylantracene-9, 10-Diones: Synthesis Computer Bioactivity Screening
KR20190032534A (ko) C5a 수용체 길항제로서의 시클릭 펩티드
EP2975046A1 (en) Novel compounds
JPWO2016143699A1 (ja) ジピリンホウ素錯体及びこれを含有する医薬
CN118239946A (zh) 作为癌症高表达蛋白（hec1蛋白）降解剂的化合物
JP2022515721A (ja) ＦＡＰαに特異的な二環式ペプチドリガンド
Arcoria et al. A fluoro-alkene mimic of Gly-trans-Pro produces a stable collagen triple helix
Awahara et al. Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor
US20250188123A1 (en) Protease inhibitors
KR20260057452A (ko) 화합물 및 용도
RU2689381C1 (ru) Хиральные S-монотерпенилцистеины

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000